Navigation Links
Prism Pharmaceuticals' Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology
Date:2/9/2009

- First time IV formulation of clopidogrel, the active ingredient in

PLAVIX(R), is studied in humans -

KING OF PRUSSIA, Pa., Feb. 9 /PRNewswire/ -- Prism Pharmaceuticals announced today that the results of the first-in-man study of PM103, a novel intravenous formulation of clopidogrel bisulfate (the active ingredient in PLAVIX(R)), has been accepted for poster presentation at the 58th Scientific Session of the American College of Cardiology (ACC) on March 29-31, 2009. The poster will be presented at the ACC's Innovation in Intervention: i2 Summit 2009 in partnership with Cardiovascular Research Foundation.

    Presentation Number: 2515-749

    Abstract Title:     Assessment of the pharmacokinetic and pharmacodynamic
                        effects of intravenous clopidogrel in humans

    Time:               Monday, Mar 30, 2009, 9:30 AM -10:30 AM

    Topic:              Pharmacotherapy - Interventional Aspects

    Authors:            Daniel Cushing, Raymond Lipicky, Peter Kowey,
                        Christopher Cannon, Michael Adams, Warren Cooper,
                        Gerold Mosher, Prism Pharmaceuticals

"We are very pleased to present the first data in humans of an IV formulation of clopidogrel at this most prestigious cardiology scientific session," said Dr. Warren D. Cooper, President and CEO of Prism. "PM103 is Prism's second acute care cardiovascular product that is being developed through our accelerated model, which focuses on bringing novel and improved formulations of existing compounds to the market."

About PM103

PM103 is a proprietary, novel intravenous formulation of clopidogrel bisulfate. Clopidogrel is the active ingredient in PLAVIX(R) (clopidogrel bisulfate), an orally available antiplatelet drug marketed by Bristol-Myers Squibb and sanofi-aventis. PM103 is being developed in collaboration with CyDex Pharmaceuticals, Inc. as an alternative dosage form to oral PLAVIX for use in the acute care setting.

About Prism Pharmaceuticals

Prism Pharmaceuticals, based in King of Prussia, Pennsylvania, is a specialty pharmaceutical company committed to developing and commercializing acute care cardiovascular products. The product portfolio strategy is focused on recognizing unfulfilled opportunities in existing compounds that address current unmet medical needs with a specific focus on medication safety in the hospital environment. Recently, Prism received FDA approval for NEXTERONE(R) (amiodarone HCl) Injection, a novel, patent-protected, cosolvent free formulation of the antiarrhythmic agent Amiodarone IV.

For further information, visit www.prismpharma.com.

PLAVIX(R) is registered trademarks of sanofi-aventis.


'/>"/>
SOURCE Prism Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prism Pharmaceuticals Appoints Maurits Geerlings Vice President of Business Development
2. New Empire BlueCross BlueShield Prism Plans Offer Better Choice and Affordability for New York Small Group Market
3. Prism glasses expand the view for patients with hemianopia
4. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
5. Prism Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
6. Prism Pharmaceuticals to Receive $10 Million Milestone Payment from Paul Capital Healthcare
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dothan, AL (PRWEB) , ... December 02, 2016 ... ... leaders from across the Dothan-Wiregrass Area in Alabama are expected to attend the ... Mike Schmitz, will help provide scholarship funds for area students and operating support ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... The annual ... Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who ... C) or prescription drug plan (Part D) need to make changes during this period ...
(Date:12/2/2016)... Hills, CA (PRWEB) , ... December 02, 2016 ... ... reconstructive surgeon in Beverly Hills, California, will be included in the 2016 “Guide ... given to exceptional professionals based on the amalgamation of their education, experience, and ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, offering local frontline ... field of pain management. , The demand for supplemental training related to ...
(Date:12/2/2016)... Texas (PRWEB) , ... December 02, 2016 , ... Yisrayl ... that delves into how this current generation fits into Bible Prophecy. Yisrayl says this ... various facts pointing to this conclusion, showing how the details line up exactly with ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... DUBLIN , Dec 2, 2016 Research ... Pipeline Database" newsletter to their offering. ... , , ... La Merie Publishing,s proprietary R&D Drug Pipeline Database provides 24/7 online ... therapeutic drugs on the market and on investigational drug candidates in ...
(Date:12/2/2016)... the largest share in the ECG Cables And ECG Leadwires ... remote monitoring ECG devices. On the other hand, the ... the highest growth rate during the forecast period. ... Company (U.S.), Medtronic plc ( Ireland ), Koninklijke ... Medical International Limited ( China ), held major ...
(Date:12/2/2016)... Quantum Radiology,s Mobile Breast Center (QR MBC) brings cutting-edge ... at the workplace, thereby maximizing convenience and compliance.  QR ... and SunTrust Bank, and community health groups to provide ... "I think it,s a great service for ... a mammogram without taking a large amount of time ...
Breaking Medicine Technology: